Your browser doesn't support javascript.
loading
Sepsis expands a CD39+ plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity.
Nascimento, Daniele Carvalho; Viacava, Paula Ramos; Ferreira, Raphael Gomes; Damaceno, Marina Alves; Piñeros, Annie Rocío; Melo, Paulo Henrique; Donate, Paula Barbim; Toller-Kawahisa, Juliana Escher; Zoppi, Daniel; Veras, Flávio Protásio; Peres, Raphael Sanches; Menezes-Silva, Luísa; Caetité, Diego; Oliveira, Antonio Edson Rocha; Castro, Ícaro Maia Santos; Kauffenstein, Gilles; Nakaya, Helder Imoto; Borges, Marcos Carvalho; Zamboni, Dario Simões; Fonseca, Denise Morais; Paschoal, Jonas Augusto Rizzato; Cunha, Thiago Mattar; Quesniaux, Valerie; Linden, Joel; Cunha, Fernando Queíroz; Ryffel, Bernhard; Alves-Filho, José Carlos.
Afiliação
  • Nascimento DC; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; CNRS, UMR7355, Orleans, 45071, France.
  • Viacava PR; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Ferreira RG; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Damaceno MA; Department of Biomolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Piñeros AR; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Melo PH; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Donate PB; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Toller-Kawahisa JE; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Zoppi D; Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Veras FP; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Peres RS; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Menezes-Silva L; Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
  • Caetité D; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Oliveira AER; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
  • Castro ÍMS; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
  • Kauffenstein G; UMR INSERM 1260, Regenerative NanoMedicine, University of Strasbourg, Strasbourg 60026, France.
  • Nakaya HI; Hospital Israelita Albert Einstein, São Paulo, 05620-900, Brazil.
  • Borges MC; Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Zamboni DS; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Fonseca DM; Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
  • Paschoal JAR; Department of Biomolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Cunha TM; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Quesniaux V; CNRS, UMR7355, Orleans, 45071, France; Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans 45071, France.
  • Linden J; Division of Nephrology, Center for Immunity, Inflammation and Regenerative Medicine University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
  • Cunha FQ; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
  • Ryffel B; CNRS, UMR7355, Orleans, 45071, France; Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans 45071, France.
  • Alves-Filho JC; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil. Electronic address: jcafilho@usp.br.
Immunity ; 54(9): 2024-2041.e8, 2021 09 14.
Article em En | MEDLINE | ID: mdl-34473957
ABSTRACT
Sepsis results in elevated adenosine in circulation. Extracellular adenosine triggers immunosuppressive signaling via the A2a receptor (A2aR). Sepsis survivors develop persistent immunosuppression with increased risk of recurrent infections. We utilized the cecal ligation and puncture (CLP) model of sepsis and subsequent infection to assess the role of adenosine in post-sepsis immune suppression. A2aR-deficient mice showed improved resistance to post-sepsis infections. Sepsis expanded a subset of CD39hi B cells and elevated extracellular adenosine, which was absent in mice lacking CD39-expressing B cells. Sepsis-surviving B cell-deficient mice were more resistant to secondary infections. Mechanistically, metabolic reprogramming of septic B cells increased production of ATP, which was converted into adenosine by CD39 on plasmablasts. Adenosine signaling via A2aR impaired macrophage bactericidal activity and enhanced interleukin-10 production. Septic individuals exhibited expanded CD39hi plasmablasts and adenosine accumulation. Our study reveals CD39hi plasmablasts and adenosine as important drivers of sepsis-induced immunosuppression with relevance in human disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apirase / Plasmócitos / Antígenos CD / Adenosina / Sepse / Tolerância Imunológica / Macrófagos Limite: Animals Idioma: En Revista: Immunity Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apirase / Plasmócitos / Antígenos CD / Adenosina / Sepse / Tolerância Imunológica / Macrófagos Limite: Animals Idioma: En Revista: Immunity Ano de publicação: 2021 Tipo de documento: Article